JP5690461B2 - 化学療法誘導嘔吐を治療するためのパロノセトロン - Google Patents

化学療法誘導嘔吐を治療するためのパロノセトロン Download PDF

Info

Publication number
JP5690461B2
JP5690461B2 JP2004553037A JP2004553037A JP5690461B2 JP 5690461 B2 JP5690461 B2 JP 5690461B2 JP 2004553037 A JP2004553037 A JP 2004553037A JP 2004553037 A JP2004553037 A JP 2004553037A JP 5690461 B2 JP5690461 B2 JP 5690461B2
Authority
JP
Japan
Prior art keywords
palonosetron
vomiting
pharmaceutical composition
chemotherapy
emesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004553037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508977A5 (enExample
JP2006508977A (ja
Inventor
マッチオッチ,アルベルト
カントレッジ,セルジオ
ブラグリア,エンリコ
ブラグリア,リカルド
Original Assignee
ヘルシン ヘルスケア ソシエテ アノニム
ヘルシン ヘルスケア ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5690461(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヘルシン ヘルスケア ソシエテ アノニム, ヘルシン ヘルスケア ソシエテ アノニム filed Critical ヘルシン ヘルスケア ソシエテ アノニム
Publication of JP2006508977A publication Critical patent/JP2006508977A/ja
Publication of JP2006508977A5 publication Critical patent/JP2006508977A5/ja
Application granted granted Critical
Publication of JP5690461B2 publication Critical patent/JP5690461B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23Updating
    • G06F16/2379Updates performed during online database operations; commit processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Databases & Information Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004553037A 2002-11-15 2003-11-06 化学療法誘導嘔吐を治療するためのパロノセトロン Expired - Lifetime JP5690461B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42682902P 2002-11-15 2002-11-15
US60/426,829 2002-11-15
PCT/IB2003/005567 WO2004045615A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012034259A Division JP5893950B2 (ja) 2002-11-15 2012-02-20 化学療法誘導嘔吐を治療するためのパロノセトロン

Publications (3)

Publication Number Publication Date
JP2006508977A JP2006508977A (ja) 2006-03-16
JP2006508977A5 JP2006508977A5 (enExample) 2006-12-21
JP5690461B2 true JP5690461B2 (ja) 2015-03-25

Family

ID=32326433

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004553037A Expired - Lifetime JP5690461B2 (ja) 2002-11-15 2003-11-06 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2012034259A Expired - Lifetime JP5893950B2 (ja) 2002-11-15 2012-02-20 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2015086840A Pending JP2015143266A (ja) 2002-11-15 2015-04-21 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2016162972A Expired - Lifetime JP6342960B2 (ja) 2002-11-15 2016-08-23 化学療法誘導嘔吐を治療するためのパロノセトロン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012034259A Expired - Lifetime JP5893950B2 (ja) 2002-11-15 2012-02-20 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2015086840A Pending JP2015143266A (ja) 2002-11-15 2015-04-21 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2016162972A Expired - Lifetime JP6342960B2 (ja) 2002-11-15 2016-08-23 化学療法誘導嘔吐を治療するためのパロノセトロン

Country Status (6)

Country Link
US (2) US20060079545A1 (enExample)
JP (4) JP5690461B2 (enExample)
AU (1) AU2003302072A1 (enExample)
CA (1) CA2505990C (enExample)
DE (1) DE10393729T5 (enExample)
WO (1) WO2004045615A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60331849D1 (de) * 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
ES2325339T3 (es) * 2006-10-24 2009-09-01 Helsinn Healthcare S.A. Capsulas blandas que comprenden hidrocloruro de palonosetron que tienen una estabilidad y una biodisponibilidad mejoradas.
EP2099298A4 (en) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE
EP2756756B1 (en) * 2008-04-28 2016-01-06 Zogenix, Inc. Novel formulations for treatment of migraine
WO2009139411A1 (ja) 2008-05-15 2009-11-19 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
WO2011058427A1 (en) 2009-11-13 2011-05-19 Helsinn Healthcare S.A. Palonosetron metabolites
ES2623503T3 (es) 2009-11-18 2017-07-11 Helsinn Healthcare Sa Composiciones para tratar náuseas y vómitos mediados centralmente
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
US20160206610A1 (en) * 2015-01-20 2016-07-21 Xoc Pharmaceuticals, Inc. Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807381A (en) * 1905-01-10 1905-12-12 Auto Stopper Company Means for securing stoppers for vessels in their caps.
US1796729A (en) * 1930-04-18 1931-03-17 Aluminum Co Of America Closure
US2069075A (en) * 1934-04-20 1937-01-26 United Dairies London Ltd Bottle or like container
US2113176A (en) * 1936-03-26 1938-04-05 Guardian Safety Seal Company Sealed receptacle
US3314564A (en) * 1965-05-06 1967-04-18 West Co Container closure
US3601273A (en) * 1969-01-31 1971-08-24 Aluminum Co Of America Pilferproof closure with vertical weakening lines
DE2315962A1 (de) * 1972-04-05 1973-10-18 Metal Closures Ltd Verschlusskappenrohling fuer flaschen od. dgl.
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
DK0430190T3 (da) * 1989-11-28 1995-08-21 Syntex Inc Hidtil ukendte tricykliske forbindelser
GB2277749B (en) * 1993-05-08 1996-12-04 Ciba Geigy Ag Fluorescent whitening of paper
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030127420A1 (en) * 2002-01-09 2003-07-10 Klaus Schumacher Dual bottle closure
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Also Published As

Publication number Publication date
CA2505990A1 (en) 2004-06-03
AU2003302072A1 (en) 2004-06-15
JP2012131811A (ja) 2012-07-12
JP2016199588A (ja) 2016-12-01
CA2505990C (en) 2009-05-19
JP6342960B2 (ja) 2018-06-13
US20110178118A1 (en) 2011-07-21
JP2006508977A (ja) 2006-03-16
WO2004045615A1 (en) 2004-06-03
JP5893950B2 (ja) 2016-03-23
DE10393729T5 (de) 2005-10-13
JP2015143266A (ja) 2015-08-06
US20060079545A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
JP6342960B2 (ja) 化学療法誘導嘔吐を治療するためのパロノセトロン
CN106421793B (zh) 用于治疗中枢介导的恶心及呕吐的组合物及方法
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
TWI434688B (zh) 選擇性s1p1受體激動劑之投藥療程
JP2965704B2 (ja) オンダンセトロンを含有する経口組成物
EA013836B1 (ru) Способ лечения послеоперационной тошноты и рвоты
EP1881832A2 (en) Use of flibanserin in the treatment of chronic pain
US7709504B2 (en) Use of Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines in the treatment of nausea and vomiting
US20070265329A1 (en) Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
KR101450345B1 (ko) 특히 토가바이러스에 의해 유발된 염증성 증상의 예방 또는조기 치료를 위한 항히스타민제의 새로운 용도
CN114502170A (zh) 阿片类药物戒断的治疗
US6455591B1 (en) Polyamines and anti-diarrheal and gastrointestinal anti-spasmodic pharmaceutical compositions and methods of treatment
TWI772992B (zh) 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
RU99128026A (ru) Новая соль
RU2018114922A (ru) Лечение очаговой алопеции
MXPA00012248A (es) Incrementadores de acetilcolina.
US20110118297A1 (en) Tivozanib and Temsirolimus in Combination
CA2874961C (en) Antispasmodic 1,2-diols and 1,2,3-triols
TW202237106A (zh) 酚系trpv1促效劑前藥之醫藥調配物
JPH01168615A (ja) 制吐作用薬剤
JP2003335703A (ja) 肥厚性幽門狭窄症の治療薬及び同治療用キット
HK1228787A1 (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1171391A (en) Compositions and methods for treating centrally mediated nausea and vomiting
HK1032911A (en) Combination effective for the treatment of impotence

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100817

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120502

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150202

R150 Certificate of patent or registration of utility model

Ref document number: 5690461

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term